Selected Publication

• Takamatsu Y, Fujita M, Ho G, Wada R, Sugama S, Takenouchi T, Waragai M, Masliah M, and Hashimoto M. Motor- and non-motor symptoms of Parkinson’s disease; antagonistic pleiotropy phenomena derived from α-synuclein evolvability? Parkinson’s Dis. (in press)
• Hashimoto M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Masliah E, Waragai M. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability. J Huntington’s Dis. 2018 Oct 26. doi: 10.3233/JHD-180309. [Epub ahead of print
• Hashimoto M, Ho G, Takamatsu Y, Shimizu Y, Sugama S, Takenouchi T, Waragai M, and Masliah E. (2018) “Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates.” J. Parkinsons Dis. 2018;8(3):405-408. doi: 10.3233/JPD-181365.
• Waragai M, Ho G, Takamatsu Y, Shimizu Y, Sugino H, Sugama S, Takenouchi T, Masliah E, Hashimoto M."Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases." Drug Discov Today. 2018 Jun;23(6):1305-1311. doi: 10.1016/j.drudis.2018.05.009. Epub 2018 May 7.
• Fujita M, Hagino Y, Takamatsu Y, Shimizu Y, Takamatsu Y, Ikeda K, Hashimoto M."Early manifestation of depressive-like behavior in transgenic mice that express dementia with Lewy body-linked mutant β-synuclein." Neuropsychopharmacol Rep. 2018 Jun;38(2):95-97. doi: 10.1002/npr2.12009. Epub 2018 Mar 7.
• Hshimoto M, Ho G, Sugama S, Takamatsu Y, Shimizu Y, Takenouchi T, Waragai M, and Masliah E. (2018) “Evolvability of Amyloidogenic Proteins in Human Brain.” J. Alzheimers Dis. 62:73-83.
• Waragai M, Ho G, Takamatsu Y, Sekiyama K, Sugama S, Takenouchi T, Masliah E, and Hashimoto M. (2017) “Importance of adiponectin activity in the Pathogenesis of Alzheimer's Disease.” Ann. Clin. Transl. Neurol. 4:591-600.
• Takamatsu Y, Ho G, Koike W, Sugama S, Takenouchi T, Waragai M, Wei J, Sekiyama K, and Hashimoto M. (2017) “Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases.” NPJ Parkinson’s Disease 3: 4.
• Takamatsu Y, Koike W, Takenouchi T, Sugama S, Wei J, Waragai M, Sekiyama K, and Hashimoto M. (2016) “Protection against neurodegenerative disease on Earth and in space.” NPJ Microgravity 2: 16013.
• Waragai M, Adame A, Trinh I, Sekiyama K, Takamatsu Y, Une K, Masliah E, and Hashimoto M. (2016) “Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease.” J. Alzheimers Dis. 52:1453-1459.
• Sekiyama K, Takamatsu Y, Koike W, Waragai M, Takenouchi T, Sugama S, and Hashimoto M. (2016) “Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases.” J. Alzheimers Dis. 52:831-841.